SEATTLE--(BUSINESS WIRE)-- The global chordoma disease therapeutics market is estimated to be valued at US$ 5,296.31 million in 2020 and is expected to exhibit a CAGR of 6.7% over the forecast period (2020-2027).

Key Trends and Analysis:

Key trends in the market include increasing research and development activities, increasing number of cases of chordoma, and increasing launches of generic versions of therapeutic drugs.

Although chordoma is a rare disease, increasing number of cases of chordoma is expected to propel growth of the chordoma disease therapeutics market over the forecast period. For instance, the American Cancer Society estimated that around 3,600 new cases of bone cancer will be diagnosed, out of which 10% cases will be of chordoma, in the U.S., in 2020.

Moreover, key players operating in the market are focused on expanding their research and development activities, in order to develop treatment for chordoma disease, which is expected to boost growth of the chordoma disease therapeutics market over the forecast period. For instance, in October 2019, Bavarian Nordic announced the completion of enrollment of the Phase 2 trial, which was initiated in October 2018, to investigate the novel targeted cancer immunotherapy drug BN-Brachyury, for the treatment of advanced chordoma. The trial is expected to be completed in January 2021.

Request for Sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/3979

Key Market Takeaways:

The global chordoma disease therapeutics market is expected to exhibit a CAGR of 6.7% over the forecast period, owing to increased approvals and launches of generic versions of therapeutic drugs. For instance, in May 2017, Dr. Reddy’s Laboratories Ltd. received approval from the U.S. Food and Drug Administration (FDA) for Doxorubicin Hydrochloride Liposome Injection, a generic version of Doxil. Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of many cancers including chordoma.

North America is expected to hold largest share in the global market, owing to presence of key players such as Pfizer, Inc., Merck & Co., Inc., and Sanofi SA, and increased prevalence of chordoma disease, in the region. For instance, according to the National Organization for Rare Disorders, around 300 new cases of chordoma are diagnosed annually in the U.S.

Key players operating in the global chordoma disease therapeutics market include—

GlaxoSmithKline Plc, Bavarian Nordic A/S, Boehringer Ingelheim International GmbH, Pfizer, Inc., Merck & Co., Inc., Sanofi SA, Astellas Pharma Inc., AstraZeneca plc, Amgen, Inc., Bristol-Myers Squibb and Company, Novartis International AG, Bayer AG, Dr. Reddy’s Laboratories Ltd., and Mylan N.V.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/3979

Market Segmentation:

• Global Chordoma Disease Therapeutics Market, By Drug Class:
  • Antimetabolites
  • Anthracycline
  • VEGFR Inhibitors
  • EGFR Inhibitor
  • Others
• Global Chordoma Disease Therapeutics Market, By Treatment Type:
  • Chemotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Others
• Global Chordoma Disease Therapeutics Market, By End User:
  • Hospitals
  • Clinics
  • Oncology Centers
  • Others
• Global Chordoma Disease Therapeutics Market, By Region:
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Related Market Intelligence Reports:

Urothelial Cancer Treatment Market, by Urothelial Cancer Type (Invasive Urothelial Carcinoma, and Non-Invasive Urothelial Carcinoma), by Treatment Type (Targeted Therapy Drugs, Chemotherapy, Immunotherapy), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Read more @ https://www.coherentmarketinsights.com/ongoing-insight/urothelial-cancer-treatment-market-3824

Small Molecule Cancer Drugs Market, by Drug Class (Alkylating Agents, Plant Alkaloids, Antitumor Antibiotics, Antimetabolites, Topoisomerase Inhibitors, and Others), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027

Read more @ https://www.coherentmarketinsights.com/ongoing-insight/small-molecule-cancer-drugs-market-2754

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200721005484/en/